RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more
RHYTHM Biosciences Ltd (RHY) - Total Liabilities
Latest total liabilities as of December 2025: AU$955.41K AUD
Based on the latest financial reports, RHYTHM Biosciences Ltd (RHY) has total liabilities worth AU$955.41K AUD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
RHYTHM Biosciences Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how RHYTHM Biosciences Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
RHYTHM Biosciences Ltd Competitors by Total Liabilities
The table below lists competitors of RHYTHM Biosciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
QES Group Bhd
KLSE:0196
|
Malaysia | RM124.77 Million |
|
Generations Bancorp NY Inc
NASDAQ:GBNY
|
USA | $322.35 Million |
|
Ping Ho Environmental Technology Co., Ltd.
TW:6771
|
Taiwan | NT$478.37 Million |
|
Econpile Holdings Bhd
KLSE:5253
|
Malaysia | RM247.59 Million |
|
Ballston Spa Bancorp Inc
PINK:BSPA
|
USA | $845.46 Million |
|
Heidelberg Pharma AG
F:HPHA
|
Germany | €43.94 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down RHYTHM Biosciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RHYTHM Biosciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RHYTHM Biosciences Ltd (2017–2025)
The table below shows the annual total liabilities of RHYTHM Biosciences Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$2.17 Million | +233.34% |
| 2024-06-30 | AU$651.54K | -64.22% |
| 2023-06-30 | AU$1.82 Million | +70.87% |
| 2022-06-30 | AU$1.07 Million | -21.81% |
| 2021-06-30 | AU$1.36 Million | +69.77% |
| 2020-06-30 | AU$802.85K | +111.44% |
| 2019-06-30 | AU$379.71K | +157.64% |
| 2018-06-30 | AU$147.38K | +16.52% |
| 2017-06-30 | AU$126.48K | -- |